行情

ASND

ASND

Ascendis制药
NASDAQ

实时行情|Nasdaq Last Sale

121.62
-0.33
-0.27%
盘后: 121.62 0 0.00% 17:02 04/19 EDT
开盘
121.46
昨收
121.95
最高
122.17
最低
119.11
成交量
22.42万
成交额
--
52周最高
183.98
52周最低
119.11
市值
65.37亿
市盈率(TTM)
-12.1513
分时
5日
1月
3月
1年
5年
人类生长激素缺乏症(GHD)药物市场前景,行业分析和前景2021-2025 |肯尼斯研究说
AmericaNewsHour · 1天前
分析师提供有关医疗保健公司的见解:Ascendis Pharma(ASND)和Merck&Company(MRK)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Merck & Company (MRK) with
SmarterAnalyst · 4天前
2021年人类生长激素缺乏症(GHD)药品市场报告不断增长,到2025年令人印象深刻的商业机会分析预测
Apr 05, 2021 (AmericaNewsHour) -- Kenneth Research recently added a report on 'Human Growth Hormones Deficiency (GHD) Drugs Market’ in its database of market...
AmericaNewsHour · 04/05 04:42
Ascendis Pharma说公司在中国的VISEN TransCon人类生长激素III期临床试验已按计划完成了目标患者招募人数
VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, announced on March 30 that it had successfully completed its recruiting target of 150 subjects for the
Benzinga · 03/31 15:52
DJ Ascendis Pharma被奥本海默(Oppenheimer)削减为表现出色
Dow Jones · 03/30 12:25
分析师解释为何他们降低对Ascendis Pharma(ASND)的评级
In a report released today, Leland Gershell from Oppenheimer downgraded Ascendis Pharma (ASND) to Hold. The company's shares closed last Monday at
SmarterAnalyst · 03/30 11:05
Ascendis Pharma A / S在ENDO 2021年的成人甲状旁腺功能减退中重点介绍了TransCon PTH 2期PaTH向前试验的6个月开放标签扩展数据
Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today presented the safety and
Benzinga · 03/23 11:10
分析人士看好这些医疗保健股:Ascendis Pharma(ASND),屈曲疗法(FLXN)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND), Flexion Therapeutics (FLXN) and
SmarterAnalyst · 03/18 10:45
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ASND最新的财务预测,通过ASND每股收益,每股净资产,每股现金流等数据分析Ascendis制药近期的经营情况,然后做出明智的投资选择。
分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ASND价格均价为196.81,最高价位219.04,最低价为169.35。
EPS
机构持股
总机构数: 248
机构持股: 6,542.39万
持股比例: 121.72%
总股本: 5,375.04万
类型机构数股数
增持
66
124.32万
建仓
32
133.23万
减持
54
161.79万
平仓
11
11.94万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.60%
制药与医学研究
-0.26%
高管信息
Chairman/Senior Vice President/General Counsel/Director
Michael Wolff Jensen
Chairman/Senior Vice President/Director
Michael Jensen
President/Chief Executive Officer/Executive Director
Jan Moeller Mikkelsen
President/Chief Executive Officer/Executive Director
Jan Moller Mikkelsen
Chief Financial Officer/Senior Vice President/IR Contact Officer
Scott Smith
Senior Vice President/Chief Administrative Officer
Lotte Soenderbjerg
Senior Vice President
Mark Bach
Senior Vice President
Vibeke Breinholt
Senior Vice President
Jesper Hoiland
Senior Vice President
Flemming Jensen
Senior Vice President
Jens Okkels
Senior Vice President
Dana Pizzuti
Senior Vice President
Juha Punnonen
Senior Vice President
Kennett Sprogoee
Chief Accounting Officer/Vice President - Finance
Peter Rasmussen
Independent Director
Lisa Bright
Independent Director
Albert Cha
Independent Director
James Healy
Independent Director
Lars Holtug
Independent Director
Birgitte Volck
暂无数据
ASND 简况
Ascendis Pharma A/S是一家丹麦的生物制药公司,主要生产罕见病治疗产品。该公司利用其TransCon技术进行治疗。该技术可应用于蛋白质、肽和小分子在内的现有药物疗法,以生产前药。该公司总部位于丹麦哥本哈根,在德国海德堡和加利福尼亚州的帕洛阿尔托设有办事处。

微牛提供Ascendis Pharma A/S(NASDAQ-ASND)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ASND股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ASND股票基本功能。